EVAXNCMHealthcare·Biotechnology#446 in industry

Evaxion A/S

+4.2% · 90d

$4.18

+0.15 (+3.72%)

After-Hours $4.18(+0.00)

News

(2)

April 2026

Apr 7, 20262 weeks ago6-KHealthcare

Evaxion A/S — 6-K Filing

EVAXEvaxion A/S

# 🧾 What This Document Is This is a **6-K filing**, which is a report foreign companies like Evaxion (based in Denmark) must file with the SEC to share material news with U.S. investors. Think of it as a formal press release submitted to regulators. This specific filing announces a clinical trial m

Read summaryView on SEC EDGAR

March 2026

Mar 30, 20260 months ago6-KHealthcare

Evaxion A/S — 6-K Filing

EVAXEvaxion A/S

# 🧾 What This Document Is This is a press release (filed as a 6-K form) announcing that the company, Evaxion, will be presenting new research at a major scientific conference. It’s a way for the company to share exciting news with the public and investors. # 🏢 What The Company Does 👉 In simple t

Read summaryView on SEC EDGAR

Key Data

Market Cap$34.9M

Open$4.26

Prev Close$4.03

Day Range$4.06 – $4.37

52W Range$1.42 – $12.15

Volume36,688

P/E (TTM)—

EPS$-1.00

Dividend Yield—

Beta0.20

Profit Margin-102.38%

Revenue Growth-100.00%

Price Target$11.25(+169.1%)

Analyst Ratings

Strong Buy4 analysts

Buy 4Hold 0Sell 0

About

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Healthcare · Biotechnology

46 employees

evaxion.ai